Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ocular Therapeutix, Inc.
Randomized, double-masked, study to evaluate the efficacy and safety of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of the symptoms of dry eye disease (DED). The subjects will be followed for approximately two months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
VAS eye dryness severity score ≥ 35 and ≤ 90 at screening.
Must not have used Artificial Tears during the Screening period.
IOP in both eyes ≥ 5 mmHg and ≤21 mmHg.
You may not be if
Have worn contact lenses in the 4 weeks prior to the screening visit and/or are unwilling to discontinue use of contact lenses throughout the study period.
Have a history of glaucoma or ocular hypertension or have a history of intraocular pressure (IOP) \< 5 mmHg or \> 24 mmHg.
